Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. (TCRT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
tcrt · stock forecast · 10 analysts (3M) · FMP · updated May 30, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Hold
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.00
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.94 | ↓ 3.02% |
1-day model range: $1.9–$1.98. Peak: $1.98 (-3.02%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -44.6% |
| 2028 | — | -57.0% |
| 2029 | — | -61.8% |
| 2030 | — | -63.9% |
| 2031 | — | -64.9% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · TCRT · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-08-15 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-08-14 | Laidlaw & Co. | Downgrade ↓ | Buy→Hold |
| 2023-05-14 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2022-05-03 | Wells Fargo | Upgrade ↑ | Equal Weight→Overweight |
| 2021-11-08 | Raymond James | Maintains | Market Perform→Market Perform |
| 2021-08-09 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2021-05-06 | Raymond James | Maintains | Outperform→Outperform |
| 2021-03-11 | Jefferies | Downgrade ↓ | Buy→Hold |
| 2021-02-28 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2020-03-02 | Raymond James | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Alaunos Therapeutics, Inc. (TCRT) stock. Of the recent 24 rating actions, 6 were upgrades and 13 were downgrades. 10 analysts currently cover TCRT.
Analyst Recommendation Trends
TCRT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
↑ 66.7% YoY
EPS This Year
$-1.67
EPS Next Year
$-6.00
↑ 258.6% YoY
EPS ForecastReported vs Estimated
Analysts forecast TCRT EPS of $-1.67 for the current fiscal year, based on estimates from 1 analysts. The TCRT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The TCRT stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TCRT price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The TCRT short-term stock prediction for tomorrow is $1.94 (-3.02%). The TCRT stock prediction for 2030 projects a range of $1–$1.
Alaunos Therapeutics, Inc. trades on NASDAQ under the ticker TCRT. The TCRT stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 10% of covering analysts.
Frequently asked questions
TCRT forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month TCRT price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.